299 related articles for article (PubMed ID: 33710277)
21. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
Fernández-Trapero M; Pérez-Díaz C; Espejo-Porras F; de Lago E; Fernández-Ruiz J
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32054131
[TBL] [Abstract][Full Text] [Related]
22. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
[TBL] [Abstract][Full Text] [Related]
23. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
24. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.
Stott CG; White L; Wright S; Wilbraham D; Guy GW
Eur J Clin Pharmacol; 2013 Apr; 69(4):825-34. PubMed ID: 23052407
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD
Chicoine A; Illing K; Vuong S; Pinto KR; Alcorn J; Cosford K
Front Vet Sci; 2020; 7():583404. PubMed ID: 33134364
[No Abstract] [Full Text] [Related]
26. Examining the Systemic Bioavailability of Cannabidiol and Tetrahydrocannabinol from a Novel Transdermal Delivery System in Healthy Adults: A Single-Arm, Open-Label, Exploratory Study.
Varadi G; Zhu Z; Crowley HD; Moulin M; Dey R; Lewis ED; Evans M
Adv Ther; 2023 Jan; 40(1):282-293. PubMed ID: 36308640
[TBL] [Abstract][Full Text] [Related]
27. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis.
Freeman TP; Craft S; Wilson J; Stylianou S; ElSohly M; Di Forti M; Lynskey MT
Addiction; 2021 May; 116(5):1000-1010. PubMed ID: 33160291
[TBL] [Abstract][Full Text] [Related]
28. Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling.
Liu Z; Martin JH
Br J Clin Pharmacol; 2018 Nov; 84(11):2483-2487. PubMed ID: 29766540
[TBL] [Abstract][Full Text] [Related]
29. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
30. Pilot clinical and pharmacokinetic study of Δ9-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain.
Clarke S; Butcher BE; McLachlan AJ; Henson JD; Rutolo D; Hall S; Vitetta L
PLoS One; 2022; 17(10):e0270543. PubMed ID: 36240167
[TBL] [Abstract][Full Text] [Related]
31. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.
Grimison P; Mersiades A; Kirby A; Lintzeris N; Morton R; Haber P; Olver I; Walsh A; McGregor I; Cheung Y; Tognela A; Hahn C; Briscoe K; Aghmesheh M; Fox P; Abdi E; Clarke S; Della-Fiorentina S; Shannon J; Gedye C; Begbie S; Simes J; Stockler M
Ann Oncol; 2020 Nov; 31(11):1553-1560. PubMed ID: 32801017
[TBL] [Abstract][Full Text] [Related]
32. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Use of Δ9-THC and Cannabidiol: Evaluation of a New Extraction Procedure for the Preparation of Cannabis-based Olive Oil.
Morini L; Porro G; Liso M; Groppi A
Curr Pharm Biotechnol; 2017; 18(10):828-833. PubMed ID: 29189144
[TBL] [Abstract][Full Text] [Related]
34. Tolerability and Efficacy of a 10:25 Preparation of Δ9-Tetrahydrocannabinol and Cannabidiol for Treatment of Chronic Back or Neck Pain: A Multiple-Dose Escalation Study.
Glare P; Chye R; Bloch M; Arya M; Moore A; Montgomery J
Med Cannabis Cannabinoids; 2023; 6(1):66-76. PubMed ID: 37465637
[TBL] [Abstract][Full Text] [Related]
35. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
[TBL] [Abstract][Full Text] [Related]
36. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
37. Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
Klumpers LE; Beumer TL; van Hasselt JG; Lipplaa A; Karger LB; Kleinloog HD; Freijer JI; de Kam ML; van Gerven JM
Br J Clin Pharmacol; 2012 Jul; 74(1):42-53. PubMed ID: 22680341
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users.
Spindle TR; Cone EJ; Goffi E; Weerts EM; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
Drug Alcohol Depend; 2020 Jun; 211():107937. PubMed ID: 32247649
[TBL] [Abstract][Full Text] [Related]
39. A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers.
Hosseini A; McLachlan AJ; Lickliter JD
Br J Clin Pharmacol; 2021 Apr; 87(4):2070-2077. PubMed ID: 33075170
[TBL] [Abstract][Full Text] [Related]
40. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia.
van de Donk T; Niesters M; Kowal MA; Olofsen E; Dahan A; van Velzen M
Pain; 2019 Apr; 160(4):860-869. PubMed ID: 30585986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
